This is the company’s fifth approval in the US after earlier approvals for Carboplatin, Paclitaxel, Epirubicin & Irinotecan. Mitoxantrone is an antineoplastic agent used in combination with corticosteroids for the treatment of advanced hormone-refractory prostate cancer. It is also indicated in combination with other treatments in the initial therapy of acute nonlymphocytic leukemia.
Ajay Vij, CEO of Dabur Pharma: “The approval represents another key milestone for the company in the US market; strengthening not only our portfolio but also our confidence of achieving one of the leading position in the generic oncology space.”